Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34+ cell therapy to induce fetal hemoglobin for sickle cell disease [CHANGE-seq]
Ontology highlight
ABSTRACT: Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34+ cell therapy to induce fetal hemoglobin for sickle cell disease [CHANGE-seq]
PROVIDER: PRJNA1160904 | ENA |
REPOSITORIES: ENA
ACCESS DATA